ArticleClinical kidney journal2026

Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.

Hong Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.